October 2, 2015
Sanofi: Genzyme Opts into Alnylam’s ALN-AT3 Hemophilia Program
Sanofi and its subsidiary Genzyme have announced that Genzyme has elected to opt into Alnylam’s investigational ALN-AT3 hemophilia program for development and potential future commercialization in territories outside of North America and Western Europe.